N ras + c Ha ras Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-18980R |
| Product Name | N ras + c Ha ras Polyclonal Antibody |
| Applications |
IHC-P
IHC-F
IF(ICC)
IF
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Pig |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human N ras + c Ha ras |
| Immunogen Range | 101-189/189 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C for 12 months. |
| Target | |
| Gene ID | 3265 |
| Swiss Prot | P01111 |
| Synonyms | ALPS4; GTPase HRas; GTPase NRas; HRAS1; N ras protein part 4; Neuroblastoma RAS viral (v-ras) oncogene homolog; NRAS; Ras family small GTP binding protein H Ras; RAS1; Transforming protein p21. |
| Background | This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene. [provided by RefSeq, Jul 2008] |
| Application Dilution | |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(ICC) | 1:50-200 |
| IF | |
Frequently asked questions
Which applications is N ras + c Ha ras Polyclonal Antibody (bs-18980R) validated for, and at what dilution?
bs-18980R is validated for IHC-P (1:200-400); IHC-F (1:100-500); IF(ICC) (1:50-200); IF. These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does N ras + c Ha ras Polyclonal Antibody (bs-18980R) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Pig.
How should bs-18980R be stored?
Store at -20°C for 12 months. Storage buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise N ras + c Ha ras Polyclonal Antibody (bs-18980R)?
KLH conjugated synthetic peptide derived from human N ras + c Ha ras Immunogen range: 101-189/189.
